ZAYO-GROUP
16.1.2023 14:01:42 CET | Business Wire | Press release
Zayo Group Holdings, Inc., a leading global communications infrastructure platform, announced the deployment of a new 400G enabled route connecting Paris and Marseille—including first-in-market network hardening of this critical route leveraging next-generation fiber technologies—to provide enterprises with an easier and more secure way to transport rapidly increasing high-bandwidth traffic from these top-ten global internet hubs.
This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20230116005067/en/
Map of Zayo's new 400G enabled route connecting Paris and Marseille (Graphic: Business Wire)
“We are continuously expanding, improving and diversifying our network in order to support our customers with their increasing bandwidth,” said Yannick Leboyer, Europe Chief Operating Officer at Zayo. “With several new subsea cable projects set to deploy in the coming years, Marseille is on its way to becoming one of the top five internet connectivity hubs globally, and Zayo is uniquely positioned to provide the necessary infrastructure to support this growth. The Paris-to-Marseille route is built to support and transport the fast-paced bandwidth growth and increasingly high demand for connectivity in these markets, giving customers a more reliable, scalable and secure way to share data to the rest of Europe and the U.S.”
Paris is the fourth largest internet connectivity hub in the world, and Marseille, a crossroad of several major exchanges between terrestrial and submarine networks, is projected to move from the seventh to the fifth largest global internet hub in the next three years. With six new subsea cables in Marseille scheduled for completion, including key gateways to Asia, Africa and the Middle East, capacity demands in Marseille are expected to quadruple by 2026. This is creating a rapidly increasing need for enterprises to transport traffic growth from these hubs throughout Europe and to other key commerce centers across the globe.
The new Paris-to-Marseille route from Zayo provides 24 terabytes of total expected capacity per fiber pair, critical triversity options, and 400G enablement for enterprises to manage this capacity growth and ensure secure, resilient connectivity to the rest of Europe and the United States. Beyond capacity, Zayo is hardening its network with new fiber technologies, making Zayo the first carrier with this next-generation fiber on the route connecting Paris to Marseille.
The route will also provide direct access to Bordeaux—the landing city for Amitié, a new private transatlantic cable that will connect the U.S. with the UK and France. Once ready for service, the connection will enable direct access to Asia, Africa, and the Middle East.
This latest investment from Zayo is part of the company’s overall strategy to overlay its European backbone and deliver high-capacity bandwidth across Europe, following the completion of its Zeus subsea cable in 2022, which provides the strongest connection between the UK and continental Europe. To date, Zayo owns and operates 2.2 million kilometers of fiber and connects 16 key metro markets and nine countries across Europe.
To learn more about Zayo’s global network, please visit https://www.zayo.com/network/.
About Zayo Group Holdings, Inc.
Zayo Group Holdings, Inc. is the leading global communications infrastructure platform, delivering a range of solutions, including fiber & transport, packet and managed edge services. Zayo owns and operates a Tier 1 IP backbone spanning 137,000 miles across North America and Europe. By providing this mission-critical bandwidth to its category-leading customers across the wireless, hyperscale, media, tech and finance industries, Zayo is fueling the innovations that are transforming society. For more information, visit https://zayo.com.
To view this piece of content from cts.businesswire.com, please give your consent at the top of this page.
View source version on businesswire.com: https://www.businesswire.com/news/home/20230116005067/en/
About Business Wire
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
Barilla Opens Global Call for Startups Through Good Food Makers 202625.5.2026 11:47:00 CEST | Press release
The program has involved over 1,100 startups across 50+ countries, delivering 26 pilot projects. Barilla Group has opened applications for the 2026 edition of Good Food Makers, its global open innovation program designed to co-develop and test new innovative solutions with startups and innovators inside real industrial environments. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260521973445/en/ Since its launch in 2019, the program has involved more than 1,100 startups from over 50 countries, leading to 26 pilot projects, with over 20 projects currently active thanks to the solutions developed by the program’s alumni. This highlights the program’s role as a concrete platform for industrial scalable innovation. The 2026 edition comes at a pivotal moment for the company, following the launch of BITE (Barilla Innovation & Technology Experience), the new innovation center dedicated to developing the next generation of food prod
JEOL: Sales Launch of the Laser SEM System “LazEdge”25.5.2026 10:16:00 CEST | Press release
JEOL Ltd. (President & CEO: Izumi Oi) has developed the “LazEdge”, an SEM system equipped with a laser processing system, and begins sales on May 25, 2026. Cross-section preparation instruments such as the focused ion beam system (FIB system), are widely used in science and technology fields across research institutes, universities, and industries. In recent years, demand is increasing for a system that can process large-areas at a high speed, while achieving high-quality of the processed surface. “LazEdge” is an instrument integrating JEOL’s SEM with the laser technology proprietary of Hamamatsu Photonics K.K., and enables laser processing inside the specimen chamber of the electron microscope. This system enables high-quality cross-section specimens produced through high-speed, large-area processing to be transferred seamlessly to subsequent analyses, such as SEM observation, elemental analysis, and crystal orientation analysis, without exposure to the external environment. As a resu
TFG-001, A Novel 3D Neural Microtissue Cell Therapy, Demonstrates Superior Functionality and Reinnervation for Parkinson’s Disease25.5.2026 08:00:00 CEST | Press release
TreeFrog Therapeutics, a regenerative medicine biotech company developing next-generation cell therapies, today announced that it will present new preclinical data on TFG-001 at the 7th World Parkinson’s Conference. TFG-001, a 3D neural microtissue cell therapy, demonstrated rapid dopamine release and extensive graft-derived reinnervation across multiple advanced translational Parkinson’s disease models—supporting its potential as a best-in-class candidate. The critical need for reinnervation in Parkinson's disease In Parkinson's disease, an estimated 60–80% of dopaminergic neurons are already lost before motor symptoms even appear. The nigrostriatal pathway degenerates, destroying the essential wiring that connects dopamine-producing neurons to movement control. While chemical dopamine replacements (like levodopa) can manage symptoms, they cannot restore the spatial precision, feedback loops, or dynamic regulation of a healthy brain network. To achieve true functional restoration, it
Galderma Receives U.S. FDA Approval for Differin® Epiduo® Acne Gel Prescription-to-OTC Switch22.5.2026 18:25:00 CEST | Press release
A unique Prescription-to-OTC switch in acne care, this approval expands access to a dermatologist-trusted, prescription-strength treatment for millions of acne sufferers ages 12 years and older Backed by more than 15 years of real-world dermatologist use and a robust clinical research program, this milestone demonstrates the depth of science behind the Differin® and Epiduo® heritage Adapalene plus benzoyl peroxide (0.1/2.5%) was the first FDA-approved, stable, fixed- dose prescription acne treatment to combine of benzoyl peroxide with a retinoid, and is now available over-the-counter The formulation is engineered to target multiple causes of acne more effectively than either of its individual active ingredients alone Galderma (SIX: GALD), the pure-play dermatology category leader, today announced that the United States (U.S.) Food and Drug Administration (FDA) has approved Differin® Epiduo® Acne Gel (Adapalene 0.1% and Benzoyl Peroxide 2.5% Acne Treatment) for over-the-counter (OTC) us
Avanzanite Bioscience’s Partner Agios Announces PYRUKYND® (mitapivat) Approval in the European Union for Adults with Thalassaemia22.5.2026 16:18:00 CEST | Press release
Avanzanite will commercialise and distribute PYRUKYND in Europe under its exclusive agreement with Agios Avanzanite is committed to collaborating with local authorities in the EU to enable access to PYRUKYND for adult patients with thalassaemia Avanzanite Bioscience B.V., a rapidly growing commercial-stage European specialty pharmaceutical company focused on rare diseases, today reported that its partner, Agios Pharmaceuticals, Inc. (Nasdaq: AGIO), a commercial-stage biopharmaceutical company headquartered in Cambridge, Massachusetts focused on delivering innovative medicines for patients with rare diseases, announced that the European Commission has granted marketing authorisation for PYRUKYND® (mitapivat), an oral pyruvate kinase (PK) activator, in adults for the treatment of anaemia associated with transfusion-dependent and non-transfusion-dependent alpha- or beta-thalassaemia, with an orphan medicinal product designation. This press release features multimedia. View the full releas
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom
